The company said an abstract on immune activation following aglatimagene besadenovec in localized prostate cancer will be presented on September 29 at the ASTRO Annual Meeting in Boston.
Candel Therapeutics said an abstract on aglatimagene besadenovec in localized prostate cancer was accepted for poster presentation at the 2026 American Society for Radiation Oncology Annual Meeting, which is scheduled for September 26-30, 2026, in Boston, Massachusetts. The poster, titled "Quantitative Digital Pathology Defines Immune Activation Following Aglatimagene Besadenovec Immunotherapy in Localized Prostate Cancer," will be presented by Francesca Barone, MD, PhD, Chief Scientific Officer, Candel Therapeutics, Needham, Massachusetts, during the session "PQA 06: Genitourinary Cancer, Gynecological Cancer and Health Care Access and Engagement" on Tuesday, September 29, 2026, from 2:15 PM to 3:30 PM ET in Poster Hall, Exhibit Hall A, Thomas M. Menino Convention & Exhibition Center, Boston. Candel described itself as a clinical-stage biopharmaceutical company developing off-the-shelf multimodal biological immunotherapies designed to trigger an individualized, systemic anti-tumor immune response. The company said aglatimagene besadenovec is the lead product candidate from its adenovirus platform and that it has completed phase 2a trials in non-small cell lung cancer and pancreatic ductal adenocarcinoma, as well as a pivotal placebo-controlled phase 3 trial in localized prostate cancer under a Special Protocol Assessment (FDA-agreed trial framework) with the U.S. Food and Drug Administration. It also said the FDA granted aglatimagene Fast Track Designation (expedited FDA review status) and Regenerative Medicine Advanced Therapy Designation for newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease, Fast Track Designation in non-small cell lung cancer, and both Fast Track Designation and Orphan Drug Designation for pancreatic ductal adenocarcinoma. Candel added that linoserpaturev, the lead candidate from its herpes simplex virus platform, is in an ongoing phase 1b trial in recurrent high-grade glioma evaluating repeat injections, and that the company’s enLIGHTEN Discovery Platform is used to create new viral immunotherapies for solid tumors. The release also included forward-looking statements on development timing, therapeutic benefit and regulatory designations, while warning that actual results may differ materially because of risks and uncertainties outlined in its SEC filings.